Stocks · News reference

William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating

Oct 16, 2026, 3:05 PMBenzinga Newsdesk

William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 8, 2026, 12:07 PMBenzinga Newsdesk
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical
EWTX
BenzingaSep 22, 2026, 11:10 AMBenzinga Newsdesk
Edgewise Therapeutics Says Preclinical Data Show Hypertrophic Cardiomyopathy Candidate EDG-7500 Improves Cardiac Relaxation While Preserving Pumping Function
EWTX
BenzingaSep 21, 2026, 10:43 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.
EWTX